Description

Salbutamol 4 mg

Brand: Magnus Pharmaceuticals
Content: 100 tablets | 4 mg per tablet
Price: €29
Manufactured in: Europe

🧪 Product Overview

Salbutamol 4 mg delivers a fast-acting β2-adrenergic agonist commonly used in airway research and cardiopulmonary modeling. Known in the U.S. as albuterol, this compound supports investigations into bronchodilation, exercise-induced asthma mitigation, airway-smooth-muscle signaling, and fat-loss models tied to β2 stimulation.

With onset in ~30 minutes and duration of 4–6 hours, oral salbutamol enables dynamic testing across acute and chronic studies. A 5–6 hour half-life supports twice-daily dosing in respiratory-performance trials, and its oral form simplifies lab handling over inhaler-based delivery.

✅ Key Research Highlights

Potent bronchodilation:
4 mg oral dose improves FEV₁ and FVC in mild asthma cohorts within 30 minutes [PubMed]

Respiratory-performance models:
Improved inspiratory capacity and reduced residual lung volume documented in exercise-based studies [PubMed]

Systemic β₂ activity:
Promotes intracellular potassium shift and raises heart rate — relevant for cardiometabolic modeling [Mayo Clinic]

Anti-doping relevance:
WADA bans all oral forms; only inhaled ≤1,600 µg/day permitted — tablet exposure triggers positive test [wada-ama.org]

Room-temperature stable:
Film-coated tablets retain potency at ≤25 °C for ≥36 months — better shelf life than inhaler solutions [nhs.uk]

🧬 Suggested Laboratory Applications

• Bronchodilation and airway-smooth-muscle pharmacology

• Exercise-induced asthma and VO₂-max modeling

• β2-agonist thermogenic & fat-loss studies

• Hypokalaemia and systemic electrolyte tracking

• Cardiopulmonary performance and heart-rate stress simulations

📊 Technical Specifications

❄️ PubChem-Supported Research Insights

• Promotes rapid bronchodilation in obstructive lung models

• Improves peak expiratory metrics (FEV₁, FVC) in dose-dependent trials

• Shown to increase cardiac output and VO₂-max in heart-failure studies

• Studied for thermogenic/lipolytic effects in β2-stimulation models

• Oral route supports longer systemic effect and steady sampling

⚠️ Documented Research Side Effects

• Common: Tremor, headache, insomnia, and tachycardia

• Dose-related: Hypokalaemia due to potassium shift

• Rare: Paradoxical bronchospasm during airway-sensitive protocols

• Cardiovascular strain at elevated exposure

🧯 Handling & Compliance

For Research Use Only — Not for human or veterinary use
Store at 15–25°C, protect from light and moisture
Purchase confirms qualified researcher status
Listed under WADA S3 (β2-agonists) — oral exposure prohibited without TUE